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Abstract
There is always room for improvement in medicine. In many areas, we can make strides and
advancements towards better treatment, but sometimes these strides although big for those giving
and receiving the treatment, can in some cases be minuscule in terms of the bigger picture of
medicine. Nevertheless, these strides, no matter their size, are all essential for the overall
progression. The issue that was chosen to focus on was the need for improvement in the scope of
Brain Tumors. Although there is much being done, it is pertinent to focus on Brain Tumors
because the tumors occur in one of the most vital organs of the body. The main issue is tumors
that occur within and around the brain, and it’s a vital issue to address because it is not so avidly
discussed in regards to cancers that occur elsewhere in the body. Through this research we will
uncover old, new, and current approaches to brain tumor assessment which directly correlate to
approaching an accurate prognosis, diagnosis, and treatment plan for patients. Upon completion
of finding all the aforementioned information, we will then speculate the precision and accuracy
available for even better prognosis, diagnosis, treatment, etc. that could become available if those
determinations were based off genetic markers commonly seen in the different types of brain
tumors.
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Chapter 1

Is there a way to further assess brain tumors in a fashion that is both concise and reliable,
in addition to being considerably more efficient than today’s common approaches?
To find whether the question above is possible, one could propose a specific approach
which could yield results that meet all aspects and requirements of a decent approach to better
evaluate brain tumors that could be generalized on tumor type (through genetic makeup) or
specialized to an individual’s particular health (and genetic makeup). To achieve a range in
specificity, this survey of literature could potentially reveal an alternative that yields a massive
array of information, all of which could be put to use in achieving the overall goal which is
patient survival and eradication of their tumor. With this new approach, using genetic markers
could be a significant advancement in medical assessment of any patient. The primary reason to
take interest into this topic is that the opportunities for progress aren’t as abundant as those for
cancers that occur elsewhere in the body, such as the breast or lung. This statement does not
serve to invalidate or diminish the severity of any of these cancers, but more so to stress that a
vital organ such as the brain isn’t as replaceable or as capable of ectomies. Breast cancers have
screening tests that are mandated after a certain age. These tests are considered “gold standard,”
which means that they are assured that all positive are positive, and all negatives are truly
negative. Lung cancer has some environmental factors that are known to increase susceptibility
such as tobacco smoking. These precautions and possibilities of early diagnosis aren’t as readily
available for brain tumors. Diagnosis of brain tumors usually does not occur unless the patient
shows symptoms that merit testing. One can only conclude from this that many patients who are
diagnosed, depending on the type of tumor they are diagnosed with, have to be in stages of tumor
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growth that has progressed significantly without notice or warning. If this conclusion is safe to
make, then it only reinforces the necessity for new approaches to brain tumor assessment. To
think that there may be a potential screening tests based on genetic markers, easier diagnosis and
treatment plans, or a concrete prognosis that yields a better outcome for the patient are all
principal reasons as to why this idea should be considered.
A future where cancers could be completely eradicated, or even more easily treatable, is a
goal to reach in modern medicine, but the path to this stage is long, full of obstacles and
setbacks, and hard to find, but that doesn’t mean it’s not worth trying. By the end of this
literature review, whether genetic markers are the possible conduits to lead medicine in the path
toward this major utopian medical ideal should be proven either as a reliable pathway for the
future or a goal unable to be achieved at this time.
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Chapter 2-

To fully comprehend this topic, it is fundamental to define some of the major terms and
concepts that will appear in this paper. Along with this background and clarification, will be the
debunking of common misconceptions about cancer and brain tumors in general. This is essential
as it sets the foundation of this research paper so that this information can serve as a foundation
for future concepts in the coming chapters.

What is cancer?

There are two types of cancers. One is malignant, and the other is benign. The types of
cancers that are benign, do not invade nearby tissue, but instead are usually encapsulated by
fibrous tissue and can grow in size with the fibrous constraints. Both benign and malignant
cancers can be removed, however malignant cancers are usually harder to completely eradicate
since they are not as well-defined as their counterparts.
“The term cancer specifically refers to a new growth which has the ability to invade
surrounding tissues, metastasize (spread to other organs) and which may eventually lead to the
patient's death if untreated”(What Are Tumors 1).
This type of abnormality can occur in any part of the human body, and sometimes,
depending on the location of the tumor, there aren’t treatment options available. In instances
such as these, patients are usually given a prognosis which may be a span of time that they are
expected to live.
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The cells in cancer that have the ability to grow uncontrollably and spread into other
surrounding tissue or organs have multiple mechanisms that allow them to do so. There are many
modes of metastasis and growth. The most common being invasion of nearby tissue (the basilar
membrane or surrounding tissue). Lymphatic spread is where the cells spread to other areas
through transportation in the lymphatic vessels where they can proliferate in a secondary site
creating a secondary tumor. Vascular spread is when the cells spread via traveling through the
veins and vessels where they can reach other organs and create a secondary or tertiary site,
creating a secondary or tertiary tumor. Lastly, angiogenesis is when the cancer cells stimulate the
growth of new blood vessels which create a blood supply and oxygen for the cells to continue to
grow, to then cause the same issues as vascular spread. As for which path a tumor will take, that
depends on the location of the tumor relative to blood and lymph vessels and nodes respectively,
in addition to some other factors that will be discussed later. But it’s crucial to keep note that all
these modes of spreading addressed are capable only in malignant tumors, as mentioned earlier,
benign tumors’ capsules that surround the tumor impede the ability of the cells to embark on the
malignant progressions. This information was learned in a biomedical science class taken at LIU
in the fall of 2017, titled Histopathology, and instructed by Dr. Anthony Capetandes.

What are tumors?
Tumors are best defined as abnormal growth, or mass, of cells. They can sometimes be
palpable depending on the location. Determining the malignancy of the tumors involves many
approaches, which will be discussed in coming chapters.
The instances where the tumors are not palpable are usually because they are not in a
palpable location, or because they are what is known as “diffuse”. Diffuse tumors are masses of
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malignant cancer cells that lack well defined perimeters and provide difficult extraction/resection
complications.
Considering the organ of interest that cancer occurs in for this paper, it is evident that this
type of cancer is of serious importance. A brain tumor can have many neurological effects on the
body. The brain has complete electrochemical control over the body. This network within your
body has a multifaceted job that one may rarely ever fully understand. To give perspective,
consider your brain to be a subway system such the New York Metropolitan Transportation
Authority. Now imagine a malignant tumor as a type of damage to the subway tracks in a local
area such as Manhattan. On the surface of the issue, the tracks may appear rusted, and one may
conclude, if the rust is removed, the subway system will be fixed and brought back to efficiency.
So, the “solution” to fix the track is implemented and for a while the tracts work.
However, a couple months later the subway tracks are not responding and there are
multiple delays for routes in Manhattan, but now also in Queens and the Bronx. Now there are
even more delays, upset customers, larger traffic flow, and potentially more crime. This is a
similar letdown that occurs when an oncologist or neurosurgeon tries to remove or destroy a
tumor.
“Maintaining an organized tissue structure is an important attribute of cells making up
any multicellular organism, whereas tumor cells lose this trait and take on a chaotic, highly
heterogeneous pattern relative to their genetic, epigenetic, transcriptomic, morphological and
biological profiles.” (Baysan et al 1). This concept of organization is termed “differentiation.”
Each cell in the human body initiated as a stem cell, and as time progresses those cells became
specialized with a given function/purpose. The cells that make up the skin offer a completely
different purpose than those in the intestinal tract, or those in the kidney. This obvious
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evolutionary advantage is crucial to any multicellular organism's continual growth and existence.
This change occurs during gene expression, where genetic material dictates what actions a cell
will take or perform.
In some instances, cells that have a high mitotic rate commonly lose heterogeneity
and their differentiated function and end up becoming what is known as a neoplasm. A neoplasm
is an abnormal growth of cells at an exceedingly fast rate, with malignant potential. In reference
to the brain, the cells that are located here are neurons, and these particular cells generate
differentiated cells called neuroblasts through a process other than mitosis. This production of
neuroblasts comes from neural stem cells in the brain. These cells remain stem cells with the
purpose of generating neurons and more neuroblasts. These stem cells are not found throughout
the entire brain, instead they are located in specialized places, such as the hippocampus and the
cerebral cortex. “Males have a slightly higher incidence compared to the females for all brain
neoplasm types except for meningiomas which effects women (80%) more than men (20%)”(J.
Gomes et al 82).
When a cell that has already been differentiated loses its purpose, it can become
cancerous or it can go through apoptosis. In instances where apoptosis does not occur, the cell
then has the potential to mutate. These mutated cells may begin to grow at uncontrollable rates.
This reaction, on the molecular and cellular level, may introduce the growth of a malignant brain
tumor. Nevertheless, there are still other factors of great significance to consider that may
possibly increase susceptibility and risk of brain neoplasm.
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Common Misconceptions
The cells of a tumor are not always uniform. This means that there can be a great
difference between one cell that lies directly next to another tumor cell. This concept, is
described as heterogeneity. This occurrence of heterogeneity in malignant tumors, especially
brain tumors, is what makes the entire treatment process (diagnosis, treatment, prognosis, etc.) so
challenging. The mutated cells that are growing uncontrollably can each have a different mutated
gene.
However, common genetically mutated cells can make up the majority, of the tumor.
These cells would be the primary target in order to achieve the main goal of tumor eradication.
This approach leads to a new problem in treatment. To eradicate a group of cells that initially
caused the proliferation of cell growth into a tumor, allows for the secondary or tertiary cells that
held different mutation to grow, and often at a more extraordinary rate than the predecessor. This
concept is called “recurrence,” and this occurs in many brain tumors. Clearly complete
eradication of a tumor that is diffuse and heterogeneous in any location would be increasingly
difficult to treat.
One would think a simple solution after eradication of a primary tumor would be to target
the recurrence with a second treatment that affect the differently mutated cells in the same way
as the first treatment plan. However, simplicity is not always a viable approach when tumors are
of concern. The crucial goal is to alleviate the patient's illness, not create more stress or harm. To
continually expose the patient to radiation or chemotherapy can result in more harm due to the
cytotoxic nature of the treatments in regard to dose and frequency. These realities must be kept
in mind if one truly desires to understand how to treat and diagnose a patient. This knowledge if
from notes in a class that was taken for the subject of Histopathology at LIU in the fall of 2017.

7

Environmental and Occupational Factors
There is a plethora of suspected environmental factors that people today think induce or
increase the risk and susceptibility of brain tumors (O. Idowu et al 1). In an article published by
the African Health Sciences Makerere Medical School, the writers assess the common
environmental factors that are believed to cause brain tumors in children. These factors include
ionizing radiation, non-ionizing radiation, N-alky-Nitrosoureas, and a few others.

Ionizing radiation is a radiation consisting of particles which is implemented in
techniques involving gamma rays or x-rays. In ionizing radiation, the energy that is used has the
ability to destroy the nucleus of an atom. This means that techniques that have ionizing
radioactive capabilities can damage DNA within the nucleus of a cell as it passes through the
tissues of the body. This is why when patients get X-rays, they are required to put on a lead vest
or apron to cover the other parts of their body that are not being evaluated. This lead vest reduces
the body's exposure to the DNA-damaging effects of ionizing radiation. With this knowledge, it
is evident why this type of radiation should be considered as a potential factor.
It is said that Ionizing radiation has a correlation to incidence of certain types of brain
tumors, especially in children. “Irradiation of the cranium, even at low doses, can increase the
incidence of meningiomas by a factor of 10 and that of glial tumours by a factor of 3 to 7, with a
latency period of 10 years to more than 20 years after exposure”(2).
Yet, when discussing specifically X-rays and their diagnostic purposes, the article states
that radiation in doses for diagnosis such a broken arm are not as harmful as their counterparts,
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such as full dental x-ray. These types of x-ray are suspected to have some correlation of
incidence(2). I t would behoove any parent to consider these possibilities in regard to both their
children and themselves. The main contradiction of this factor is that Gamma ray radiation is
used to target specific malignant cancers due to the ability to destroy the DNA of a cell. There is
a procedure that exists with the sole purpose of killing cells in a selected area that uses Ionizing
radiation. This procedure is called Gama Knife Radiation therapy, and since it is used in a
therapeutic procedure as a way to destroy cell, it will not be included in this discussion of
environmental factors that could affect brain tumor risk. However, this procedure, if enacted,
brings up an ethical question as to whether or not this usage should be continued as a form of
treatment, knowing that it would be targeting all cells not just the cells of the tumor.
Non- ionizing radiation does exactly what it states. Unlike its previously discussed
counterpart, Non-ionizing (NI) radiation does not cause ionization through radioactivity. This is
because NI radiation uses electromagnetic radiation that does not have the same amount of
energy as Ionizing radiation. The types of instances where one may encounter NI radiation are
near powerlines, microwaves, or infrared radiation. Radiofrequencies are also included in this
list and the can be encountered daily by mobile/cellular use. However, “Recent data in humans
do not support the hypothesis that the use of hand-held cellular telephones causes brain tumours
”(O. Iduwo et al 2). As for power lines, this form of NI radiation, in essence from what was read,
has no evidence of contributing to increased incidence in brain tumor malignancy.
N-alkyl-nitrosoureas is a particular compound, known for its alkylating properties to
DNA. It is also known to cause brain tumors in lab rats. One of the reasons this particular
compound was considered a factor to be assessed for correlation of incidence is because it has
the ability to pass through the placenta to the fetus. This compound can be found in meat
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products and possibly contaminate water, however the studies conducted by the researchers from
the African Health Sciences states that there has yet to be found any substantial results of
correlation between human brain tumors and the compound.
One of the other factors that was included in this research as an environmental factor is
viral infections. There have been many speculations, that some viral infections such as HIV may
correlate to certain types of brain tumors in children. This has been researched extensively, yet
there are no conclusive results that indicate a concrete relationship of causality between viral
infections and brain tumors. Consequently, it is safe to conclude that, as of now, the principal
environmental factor of concern, in its’ relation to incidence and susceptibility/ risk increase, is
Ionizing radiation.
As for adults, they are also at risk for the same environmental risk factors discussed
previously, as well as some occupational rick factors. This list or factors in total that was
discussed and assessed by The International Journal of Occupational and Environmental
Medicine are
“exposure to diagnostic and therapeutic radiations, electromagnetic radiation from
cellular phones and other wireless devices, infectious agents, air pollution and residence
near landfills and high- voltage power lines and jobs as firefighters, farmers, physician,
chemists and jobs in industries such as petrochemical, power generation, synthetic rubber
manufacturing, agricultural chemicals manufacturing.”(J. Gomes et al 82).
In the article authored by J. Gomes et al, the environmental and occupational factors have
substantial research which indicates that there may be a correlation between certain occupations
and an increased risk of primary brain tumors (specifically intracranial malignant gliomas,
10

astrocytomas, and meningiomas). Consult Appendix B for the occupation and the suspected
level of risk due to exposure.
Other not so common occupations that were mentioned by J. Gomes et al are those in
hazard cleanup and those that work with/near metals. Jobs where workers were introduced to
arsenic and mercury were correlated to brain neoplasm incidence increase. Occupations with
hazard cleanup saw a slight increase in incidence of brain neoplasm in those who worked on the
nuclear radioactive cleanup of Chernobyl (92). Evidently occupational and environmental risks
are not as clear cut. The subject area of brain tumors and their incidence through outside factors
contains a large gray area. The principal goal of future research into this topic will most likely
center around finding a gold standard outline to each brain tumor's cause, treatment, prognosis
and diagnosis.
Exclusion of certain factors are due to limitations such as small population size;
differences in parameters of assessment in exposure in terms of latency, exposure time, etc.; age,
ethnicity, co-exposure, and more. However, this does not negate or invalidate the aforementioned
findings for correlation with primary brain tumors. The best approach would be to minimize the
limitations uncovered by J. Gomes et al by exploring studies that find possible effects on an
almost universal or standardized basis. These would need to have parameters the could produce
results that are reproducible and accurate, with group of the same tumor type, similar age, and
social/economic factors.

What are genetic markers?
Molecular information like this offers solid evidence that can be securely used without
much room for doubt. “Genetic markers are variants in the DNA that are associated with a
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specific disease phenotype revealing variations DNA Marker technology has revolutionized the
world of genetic research… A marker may have functional consequences, such as altering the
expression or function of a gene that directly contributes to development of disease.” (S. Raza et
al 221). Chiefly put, genetic markers are like guide maps that can help a doctor better figure
which tactics to employ when treating or diagnosing a patient, and this is made possible due to
their expression, suppression, or location relative to other genes.
Whether it is multiple mutations, single mutations, whole chromosomal gains or losses,
or even wild type genes, any of these genetic markers could be used. Scenarios where physicians
cannot agree on issues involving their patients’ health or uncertainty in any biological test can
possibly be swayed if specific, individual molecular and biological information is used as a map
to concise information for the patient and their health.
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Chapter 3
Classifications of Brain Tumors
Early Classification
The World Health Organization (WHO) is an entity that represents information found by
a committee of specialized doctors and surgeons that consult on criteria used for the
determination and assessment of particular diseases. In addition to this, WHO also applies these
evaluations to new findings and information. The conclusion made by the members are used on a
universal basis (but not mandated to be used), so that when a patient is diagnosed there are not
any discrepancies or confusion on why or how they were diagnosed with a specific brain tumor.
For consistency, only classification systems from the WHO classification of tumors of the Brain
Central Nervous System will be used. This is compiled of the information proposed from 117
contributors from 20 different countries in the 2016 edition, in addition to all previous editions
of the classifications to illustrate to the reader the progress that has been made over the years. (D.
Louis et al 2)
The history of the classification system for brain tumors starts in 1979. The first edition
of the WHO classification was published that year and it assessed how to determine what brain
tumor a patient should be diagnosed. This work matured over the years and offered numerous
notable advancements that are now put to use in many aspects of tumor assessment around the
world. This particular edition did not offer as much as it progenies, but it’s significance still
stands as the first step of many that helped oncology and medicine reach all the accomplishments
that have been achieved so far (B. Scheitauer 1-4)
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In the early 1990’s , the second edition of the WHO classification was published, and like
all new editions, new information such as types of tumors and variants were introduced. At this
time, the use of this classification system was still optional. The only well-known approach to
tumor classification was based on histopathological appearances, and these classified tumors
formed a short list that included some of the most significantly assessed tumors as of recent
publications, such as different astrocytomas and meningiomas. Different, meaning in their
morphological appearance regarding to shape, color (density of color), and the rate at which the
cells proliferate.
In this histopathological approach a new technique of assessment was introduced.
Tumors such as the “monstrocellular sarcoma” , were renamed on the basis that the
“immunohistochemica1 studies clearly showed that tumour cells consistently express GFAP” (P.
Burger et al 262). GFAP stands for “Glial fibrillary acid protein.” It is a common protein that is
found in cells in the central nervous system such as astrocytes and ependymal cells. GFAP can
be detected by immunohistochemistry. In immunohistochemistry, antigens are imaged by using
known biological assets (antibodies) of the tissue selected which will bind to the antigens. This is
done so that once the binding has occurred, the antibodies which can be seen under a microscope
will indicate what ailment the patient has. This technique uses markers specific to the particular
disease to help determine what cannot be decided based on a macroscopic basis
(Immunohistochemistry Principle ). This change in classification based on a molecular
parameter is significant because it illustrates the major blind spot that was in medicine before its
implementation.
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Early Tumor Grading
Guidelines were also introduced that detailed which characteristics of tumors should be
seen in order to grade the level of malignancy. Some of these characteristics included
requirements and observations such as proliferation rate (whether it be fast or slow), ability to
invade nearby tissues, necrosis and atypia. The third edition was published in 2000, and differs
from it’s to ancestors in that it has additions such as predictive features of new tumor types,
along with descriptions of the entities in clinical, radiological, and other biological aspects (D.
Louis et al 215). This edition contains the major turning point for brain tumor classification. The
inclusion of genetics as a defining feature in naming tumors has finally come, and with its
introduction, the products that were generated led oncology down a sturdy path to better overall
tumor assessment.
The WHO grading system in this edition was set forth as a guide to depict the level of
tumor malignancy. For instance, this excerpt from The Journal Neuropathology and
Experimental Neurology below discusses the genetic content that lead to the changes in grading
of certain tumors.
“Astrocytic brain tumors span a wide range of neoplasms with distinct clinical,
histopathological, and genetic features. Molecular genetic data that has been gathered
since the prior WHO classification in 1993 suggest that individual histologically defined
types of astrocytomas are even more diverse at a biological level”
In addition to this discovery, they found that glioblastomas are characterized by amplification of
a particular gene, in addition to some other special proteins expression and suppression. These
attributes helped label the glioblastoma as a primary grade II brain tumor. For secondary
glioblastomas the criteria applied to their grading were the occurrence of TP53 mutations that
15

arose in over half of their cases , and in over eighty percent of their cases for anaplastic
astrocytomas. (219).
The most noteworthy additions to the new edition are the newly recognized mutations
and deletions that gave enhanced insight into the tumor on a more structural level. Chromosomal
changes are mentioned, indicating that there’s great potential behind the use of these parameters
in aspects other than classification. This article speculates the strength and practicality that this
genetic information could offer in terms of clinical approaches, and even treatment plans. It is
pertinent to acknowledge that the editions preceding this third edition, although not mandatory
to be used, shows the continual effort put in bettering the patient and doctors understanding of
brain tumors, and possible causes or commonalities among tumor types, and that should be
admired.

Recent Tumor Grading

The 2007 publication discussed more generalized parameters that offered a further
breakdown of the classification system. These new attributes that led to this accomplishment is
the addition of information such distribution of occurrence in age or gender. Location of the
tumor and the way the tumor progresses during clinical trials were also factored into this system.
This new edition had contributions from a plethora of individuals and countries that collaborated
to aid in furthering the usefulness of this classification system so that it can be used on a
universal basis at one’s discretion.
Examples of these parameters’ enactment include the change of Pilomyxoid astrocytomas
from its original grading to a WHO grade II, based on its common patient distribution among
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infants and children as stated in the article, in addition to its poor prognosis. There is also the use
of CNS as a prefix when naming a particular subtype of tumor, specifically CNS neuroblastomas
or CNS ganglioneuroblastomas, due to neuronal differentiation or the presence of neoplastic
ganglion cell respectively (D. Louis et al 10).
One of the elements that stayed the same through this 2007 edition was the format used
for grading brain tumors. A complete breakdown of what qualifies each type of tumor from
grade I to grade IV is depicted below (10).
For Grade I, the cells have a low proliferation rate, and there is a possible potential of
curing the patient through removal.
For Grade II, these tumors are understood to have some notable infiltrating and
proliferation potential, and a possibility of recurrence. Some Grade II tumors can even
progress into high grades.
Grade III tumors are known to be malignant capabilities, high proliferation and cell
division, and commonly require chemo and radiotherapy.
Finally Grade IV tumors, which is the worst grade of all in terms of prognosis, known for
pre and post disease evolution and fatal outcomes, are seen to have necrosis in
surrounding tissue, extreme malignancy, and widespread infiltration and possibly
dissemination.
After 2007, there was almost another decade before the fifth edition was published in
2016. In this edition of the WHO classification system, a table that lists all the changes that were
made from the previous editions depicting new variants, tumor types, histologic or genetic
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findings, etc., along with a table of their current grading system for a select number brain tumors
was included. (see appendix C)

In respects to classification, the breakdown of how malignancy grades of brain tumors are
simple to understood, but this should not be mistaken as the universal breakdown for all tumors.
In actuality, to determine the malignancy grades that can be given to a tumor, first the tumor
itself must be classified, and other tumors similar to it identified. This is done by first looking at
the location of the tumor. Particular tumors have common location within the brain that they
occur such as the cerebellum for medulloblastomas, or in the posterior fossa for ependymomas.
Then, the next aspect to consider in grading is the size of the tumor, and whether its looks
concise with clear borders or diffuse with unclear indication as to where it starts and end. After
determining these macroscopic characteristics, one can then embark on the microscopic and
molecular parameters to assess the tumor. This will consist of immunohistochemical assessment
for common marker that indicate proliferation rate, mitotic activity, and more information to
determine the level of malignancy. With these finding, this could help differentiate between a
tumor that may appear to have a clear prognosis, but highly malignant and aggressive cells on
the molecular level that indicate high potential of invasiveness or mortality; meanwhile another
tumor that appears diffuse at the macroscopic level can present immunohistochemical data that
indicates low recurrence rate after resection. It is because of this that malignancy grades in
tumors are specific for each tumor type.
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Nomenclature
In addition to the latest provisions, the newest edition of WHO classification included an
acknowledgement of progressive information that was withheld from the 2007 edition. This
information was not included due to the unknown plausibility of this information to stand alone
as its own factor instead of a subcategory or aspect of a larger condition or component in the
classification process; A breakdown of how the names are written; common challenges and
obstacle faced; and new variants are present in all new editions.
D. Louis et al stated that the combined use of phenotypic and genotypic parameters
heightened and cleared the missing aspects of diagnosis. With this approach, which now include
genetic information which could also be called genetic markers, could theoretically provide
improved accuracy in diagnosis, patient management, and prognosis of brain tumors and cancers.
As for the nomenclature , the names follow a setup similar to most classification systems,
where there’s a hierarchy to what order the information should be mentioned for each type of
tumor. Most tumor classifications have the histopathological name with the genetic features
following after a comma. One example given in the text is “diffuse astrocytoma, IDH-mutant.” If
there were multiple genetic features, then they were both included in the name. If there was a
lack of genetic information due to unattained molecular diagnostic testing, then some tumors
received the designation “NOS” which stands for, “not otherwise specified.” (D. Louis et al 11)
Nevertheless, with progress, there’s always a new obstacle to address and resolve. This
issue in the recent edition was labeled as “discordant results,” or in other terms, conflicting
results. When histological results contested with molecular genetic results, there was the issue of
deciding which piece of information should be used, and which should be disregarded, in order
19

to properly name particular tumors. The decision to use genetic information when there was
conflict with results solidified the efficiency of genetic markers' capability and strength in brain
tumor research advancement. Certain brain tumors from this classification of a tumors in the
central nervous system will be used as focal points to show support for the use of genetic
markers in the discussion on what should be done if there’s a way to readily identify specific
tumors. In doing this, an explanation as to whether the assertions that were made can be
validated, in order to exemplify the indisputable weight that genetic markers could carry in
medicine.

What to do with new findings?

With this clarification comes another aspect that should be addressed. This issue is the
malignancy of the entire tumor. Until now, it may have been presumed that the whole of the
tumor mass is malignant and dangerous. This would be a precarious assumption to make, but to
avoid any discrepancies or confusion, its pertinent to state that the malignancy of a tumor is
usually determined by a focal point of the mass, as found by V. Collins. Because there is a
specific section of the tumor that expresses characteristic of malignancy, these sections should be
assessed in detailed in order to give the proper treatment.
Toward the conclusion of the article for the 2000 edition of WHO classification, P.
Kleiheus et al states that the opportunity of “… assessing whether a tumor with a particular
molecular feature responds to a specific therapy may provide important information about
choosing among currently available treatments and for the design of future therapies, regardless
of whether any prognostic information is provided.” (P. Kleiheus et al 223). Added to this was

20

the discernment that the new entities that came about as a result from genetic typing helped to
establish gene expression patterns that could be used to easily predict an individuals’ response to
different types of therapies and treatments (223).

Essentially, a full tumor assessment should be made before treatment or therapy courses
are taken. Consider having a load of laundry that one is in a rush to clean, and in that load is a
red sweater that can ruin all the other clothes. Associate the importance of separating your
laundry and compiling all the proper colors into the correct piles as the same steps that need to be
taken in assessing a tumor before treatment can be implemented.
Information such as patient history is similarly important. It should be understood that
brain tumors have a multifaceted complexity, and that all information as to lifestyle,
environmental factors and occupational factors is necessary in order to classify the tumor, but
also to treat the tumor.
The implications of this new standard approach should consequently aid in deciding
prognosis, treatment and therapy, and, in some instances, clinical trial selection. A
“neuropathologist may be expected to make a diagnosis on the basis of often very small and
fragmented biopsies” (V. Collins et al 1), and it is crucial to take the patients and patients’ family
medical history into consideration in order to make the best diagnosis , in addition to
collaborating with other medical professionals, as a collaboration would offer better insight than
a single doctors' findings.
The brain tumors that most commonly occur for adults are diffuse astrocytic tumors,
oligodendrogliomas and meningiomas, while pilocytic astrocytomas, ependyomas, and
medulloblastomas are commonly found to occur in children(V. Collins et al 1). A synopsis of
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information similar to this, and on the aforementioned tumor types that can be used as a
reference point, illustrating the information from the different editions classifications systems
and other sources can be found in appendix E. When reading the coming chapters, this synopsis
along with the other figures can serve as elucidations to offer a better understanding as to why
brain tumor approaches, prognosis, treatment, and diagnosis are different for each tumor.

Current Assessment of Brain Tumors
There are multiple ways to observe a brain tumor and its effects on the patient. The
options available are MRI, Tissue sampling/biopsy, CT scans, Positron emission tomography
(PET) Scan, Cerebral , arteriogram/angiogram, Lumbar puncture/spinal tap, Myelogram,
Neurocognitive assessments, and Electroencephalography (EEG). However, the only approaches
that will be assessed in this thesis are MRI, CT-scans, Tissue sampling, and Lumbar
puncture/spinal tap.
For MRIs, the primary information that could be concluded is tumor size, location and
enhanced imaging. “Some studies suggest that tumor location affects survival and may play a
role in prognosis” (N. Mickevicius et al 394). An article published by The journal of
Neurooncology, discussed the capability of viewing brain tumor intersecting white matter as a
way to predict patient prognosis. Through MRI, this article discussed whether total or
subtotal/partial resection of tumors would be the best route for treatment based on MRI images
that showed tumor cell migration along the path of white matter tracts.
The results of this approach to tumor treatment and prognosis through use of MRI
showed crucial information about tumors in regard to the tissue they invaded, their location, and
other finding correlated to drug treatment. To comprehend the coming material see Appendix F.

22

With these findings, it obvious that MRIs do offer great insight into brain tumor
treatment and prognosis. And when combined with other approaches, this could yield a highly
plausible tactic to better treat brain tumor patients and give more accurate prognoses.
When considering which treatment course to take, the entire tumor and even seemingly
unaffected areas around it are all of great importance. Medical imaging procedures and
techniques are used to view these areas to help give oncologist a better idea of how to treat an
individuals’ particular brain tumor. One of these techniques is the computed tomography, or CT
scan.
CT scans create images which help to decide dose level of a particular treatment path a
patient should be prescribed. N. Mickevicius et al found that CT scan slice thickness, in relation
to tumor size, does have a correlation as to which treatment plan and dose a patient should have.
The size and planes the CT scans are taken in can range from 1, 2, 4, 6, and 10 millimeters, and
can be in the sagittal, coronal, axial, and arbitrary view respectively.
Corresponding article, by R. Caivano et al found the same conclusion when conducting a
study with a spherical mass which “showed that for targets less than 1.5 cm in diameter, it is
reasonable to acquire CT images with the smallest thick- ness available. They also
recommended, for conformal radiotherapy treatment planning, 4 and 8–10 mm CT slice
thickness for targets between 1.5 and 3 and for targets greater than 4 cm in diameter,
respectively.”(R. Caviano et al 507). Both N. Mickevivius et al and R. Caivano et al essentially
found there is an optimal slice thickness in tumor treatment planning for tumors or particular
sizes. It is findings such as these that may seem simple, but in actuality take a significant amount
of time to compile the necessary data and information to make such solid assertions.
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When using techniques such as CT scanning, information is provided to an oncologist
and whomever they collaborate with interprofessionally when consulting with a patient on
treatment plans. However, the specificity and detailed needed for differences in tumor size in
relation to slice thickness and angles show that this option, although helpful, is difficult. This
technique can be seen as exceptionally trying when the patient has to go through multiple
imaging sessions to find the appropriate slice thickness and angles to their particular brain tumor.
For lumbar puncture and spinal taps, cerebrospinal fluid (CSF) is used to determine if the
DNA found in this fluid offered any insight to the brain tumors in the patients. The motivation
behind this was that cerebral spinal fluid can be assessed for genetic material such as Cell free
DNA. In the article that discusses this medical approach, written by Wenying Pan et al, the
method of this technique included the sample being taken and amplified using polymerase chain
reaction (PCR) with targeted amplicon sequencing to increase and concentrate the important
DNA found within the “liquid biopsy”.(W. Pan et al 2).
In this approach, the scientist found that they were able to detect tumor mutations within
the CSF from Cell-Free DNA, and that these samples included both primary and metastatic brain
tumor mutations from the pool of the seven patients they assessed. The DNA found in this
experiment is called Cell-Free DNA, meaning that it was found outside of cells in the CSF from
a tumor. This type of DNA is particularly hard to extract, hence the need for PCR to increase the
quantity of DNA found so that it can be efficiently analyzed. The suspected reason for the
difficulty is that the blood brain barrier may hinder the movement of the Cell-Free DNA to travel
through the body.
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This is of significant importance because it demonstrates the great potential of tumor
content assessment without the invasive approach which requires collecting brain tissue that has
been affected by a tumor. This ability to detect mutations led to the innovative advancement to
“characterize tumor mutations in CSF for potential clinical diagnosis”(2). The information
derived from the mutations were the detection of known driver mutations, which were capable of
allowing the researches in this article to keep watch over brain metastasis; and “global
characterization of genomic aberrations to direct personalized cancer care.” (3).
Driver mutations are mutation that drive the malignant spread of a tumor. These genomic
aberrations are created as a byproduct of the breakdown of the machinery used in DNA
replication. These aberrations are classified as duplications, deletions, translocation, and other
genetic based changes (M. Guttman et al 1). One strategy assesses focal points of mutations in
CSF, and the other strategy used by Wenyin Pan et al, assess genomic aberration through panel
sequencing with known DNA aberrations found in cancer genes. These strategies lead to the
conclusion that brain tumor mutations are conveniently easier to detect in cerebral spinal fluid
than in plasma (W. Pan et al 2).
The conclusion of this article for assessing CSF weight in tumor treatment and prognosis
is explained in the excerpt below.
“The first strategy, an approach based on digital PCR and targeted amplicon sequencing,
is cost effective and highly sensitive. … For patients who have had tumor resections,
their tumor mutations can be identified from the surgical sample with standard clinical
tests, such as sequencing or genotyping arrays. …The tumor types that most commonly
metastasize to the brain, such as breast, lung, and melanoma, have well characterized
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hotspot mutations amenable to this strategy. The second strategy… has potential to guide
personalized cancer therapy, monitor residual disease, and track the evolving tumor
genome ”(9).

Clinical Approaches to Brain Tumors

Clinical trials are used to test potential agents and therapeutic substances to determine
whether they are successful enough and efficient enough to be administered to patients on a
larger scale. M. Gilbert published an article titled, Facing the Future of Brain Tumor Clinical
Research. In this article, the clinical trials that were assessed were cytotoxic chemotherapy
agents, signal transduction modulators, biological agents, antiangiogenic agents, and
immunotherapies .In addition to the types of substances used, the method of introduction of the
substances into the patients was also considered. The Studies researched showed low efficiency
in treatments that used drug capable of crossing the blood brain barrier, so alternative options
that used direct injection, implantation of slow release vehicles, and other approaches were used
instead (M.Gilbert et al 2).
The issues that consistently hindered clinical approaches were believed, to stem from
inherent heterogeneity and continual genomic transformation of the cancer, the integrity of the
blood brain barrier, and unique microenvironments consisting of glial cell, microglia and other
cell types(5). Other issues mentioned were the size of the population diagnosed with the
particular tumor type being assessed; or patients who do have the diagnosis of the desired
tumored being too far in progression, unwilling to participate, or no knowledge of clinical trials
available (4).
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These clinical trials and approaches are well-intentioned, and some do offer great
advancements. The way this progress in the trials is assessed is through patient health,
categorized as Overall Survival (OS), Progression-Free survival (PFS), and Response Rate (RR).
The FDA has declared the evidence of symptomatic benefits is a meaningful criteria as a
measure of clinical benefit as well. The system used to check the symptoms each patient has is a
list of 23 items where the patients are asked to describe how the symptoms affect them on the
daily and the severity of their symptoms. Its hoped that there will be progress made on a better
system as this seems to be too narrow of a spectrum for symptoms patients feel or don’t feel.
Clinical approaches to date still have major advancements sets before them. This does not
invalidate or discredit the value of the information that has been found, but serves to filter to the
audience that information found here still needs work. Circling back to the point made earlier
that everything will continually need improvement as we go through time, to recover a potential
path towards what could be the next significant approach in medicine for brain tumors would be
an astounding achievement.
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Chapter 4
Drawbacks
The drawback from using MRI technology is that this technique, along with the others, will not
be used until the patient expresses symptoms similar to those expressed in people who have brain
tumors. This technique has significant use, but this is mostly the case when it combined with
other procedures, and not so much when its’ on its own. MRI can help diagnose brain tumors,
and can be useful in determining patient progression, but the need for improvement can never be
fulfilled.
To achieve better results for patients with brain tumors, there needs to be a technique that can
offer universal or multifaceted applications to keep pace with the multifactorial complications
found in each type of brain tumor. These aforementioned techniques of MRI and CT scan
imaging can help with this development, but they are not capable of being the face of process.
Spinal tapping/lumbar punctures are seemingly good perspectives as ways to achieve and overall
better patient assessment of an individuals’ tumors, but this task also needs to be further studied
to assure its reliability.
These procedures are still significant, and should continue to be used, but the face of this
golden approach should be genetic markers. The information and resources cited in this paper
had one common factor, which was the inclusion of common genetic phenomena. These
phenomena were genetic mutations, common chromosomal changes, genetic expression such as
GFAP, and more. These phenomena were seen in the classification system, the diagnosis of
tumors, and the predictive prognosis of patient health and treatment.
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Plausibility for Genetic Markers?
One of the common pathways that are altered in tumors is the process of programmed
cell death. For Apoptosis this pathway called the p53 pathway, is commonly mutated in
carcinogenic cells of brain tumors. The gene TP53 regulates the cells of the body, and when it’s
time for a cell to die, this pathway will be enacted. But with this gene is mutated, the original
capability of the gene to stop proliferative growth and other tumor suppressive attributes are
destroyed.
The information published by G. Fulci et al on p53 and its relation to brain tumors was
found in 1998. These findings showed that genetic markers use has been essential for decades in
better understanding tumors (G. Fulci et al 1)
When planning treatment courses, the genetic make-up of certain cells in a heterogeneous
tumor mass can be assessed, to pick treatment plans that can target all the cells based on their
genetic expressions. And, in instances where tumor heterogeneity leads to recurrence, this too
can probably be concluded by assessment of the primary tumor and the genetic expression found
in it relative to the secondary tumors.
As for patient prognosis, in the classification system, there were tumors that are known to
have poor prognosis based on previous cases where mortality was within months of diagnosis,
but if a genetic parameter could be used to screen for this type of malignant growth/cell type,
then prognosis although not positive, would still be well founded in cases where the range of
months could differ from 6 to 8 moths in difference per each brain tumor type of high
malignancy and mortality.
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In an article published by the Journal of Neuropathology & Experimental Neurology, J.
Roth et al uses the genetic change of an entire chromosomal gain and its commonality in relation
to the possibility of a brain tumor return after a surgical removal. The tumors used in this
assessment were Pilocytic astrocytoma (PA) and a variant of it. The researchers conducted a
retrospective analysis of the information attained from patients who were diagnosed with PA
from the years 1998-2014. The patient size in total for this research was 116, with 122 tumor
specimens.
In the experiment the researchers discovered a 2.0 M.b. gain on chromosome 7 in a band
named 7q34, and that this genetic change resulted in the KIAAI1549-BRAF fusion. The fusion
occurred in 74% of the 116 patients they had specimens from. Other sightings included different
chromosomal changes such as gains for the chromosomes 5,6,11,15,and 120. The relationships
between co-occurrence of each type of genetic changed mentioned were also assessed (i.e.
Chromosome 7 gain with BRAF fusion, or BRAF fusion with other chromosomal gains), but
these statistics were insignificant as the percentages of co-occurrence was low, and showed no
correlation to information on tumor recurrence. Through assessing every aspect of this
information and other statistics mentioned in the article, the researchers concluded that
chromosome 7 gain showed a significant increase risk of recurrence than those patient specimens
that did not have chromosome 7 gain. Through the analysis of the genetic changes present in
patient specimens, researchers were able to conclude a prognosis of PFS, and possibility of
recurrence. (J. Roth et al 2)
The international Journal of Cancer did a similar assessment on glioma stem cells to
determine if any genetic changes offered any significance to an increase in the possibility of
recurrence. In this study by M. Baysan et al, the specimens used are glioma stem cell lines ( both
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polyclonal and monoclonal) from an initial tumor diagnosis, along with tissue samples from the
same patients’ recurred tumor after they deceased. Unfortunately, one of the findings in this
article states that in terms of comparison between the initial tumor specimen and that of the
recurrent specimen taken after death showed no common mutations. However, this seemingly
significant blow to the use of genetic markers was completely evaded. It turns out that the reason
the common genetic mutations found in the initial tumor sample were not found in the recurrent
tumor was because the treatment plan to eradicate the initial tumor was successful in the
eradication of the tumor mass by killing a targeted cell type within the tumor; and because this
eradication was successful, the cells that took over the proliferative properties of the initial tumor
were able to grow and spread, causing the recurrence.
“It would appear that in this particular patient, selective pressures presumably from
radiation, various cytotoxic and antiangiogenic agents succeeded in eliminating the
original high-proliferating clone that dominated at disease presentation. Subsequently,
however, there was an emergence of a distinct invasive clone that predominantly
localized to the corpus callosum and contralateral hemisphere. Although most
glioblastoma transiently respond to initial therapy, tumor recurrence is inevitable and
ultimately leads to the patients’ demise.”(M. Baysan et al 12)
The outlook for patients may seem to be grim, but the need for advancement still lives. In
the section where the researchers discuss genomic results, the authors found that a particular
homozygous mutation of focal P16 deletion and homozygous p53 mutation were found
consistently in all their samples, and correlated that these same genetic markers were seen in
“Homozygous focal p16 deletion and homozygous p53 mutation were among the wellmaintained events across all our samples. Moreover, these events are highly recurrent in GBMs
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in general”(8).Although the search for common mutation between recurrent and initial tumors
was unsuccessful, the common mutation of any GBM were still found, thereby endorsing the
value of genetic markers.
New information found through the assessment of chromosomal gains and losses of
chromosome 7 and 10 respectively, were speculated to indicate that as time passes, the buildup
of mutations can indicate the “clonal age for the monoclonal GSCs” (10) in instances where
mutation accumulate over time. In addition to this, the researchers concluded through a whole
overview of the data and information found, that it is strongly advised to re-biopsy a patient with
GBM before they treat with any targeted therapies, since the finding that illustrated new tumor
cells in a recurrent tumor will need a new approach to destroy the newly dominant cells (12).

Conclusion
From the data, statistics, experiments and other information presented in this work, it’s
evident that Genetic markers offer a promising approach to tumor classification, prognosis, and
treatment. The hypothesis is this paper was to determine whether Genetic Markers are capable of
being used as screening test for brain tumors, along with their ability to aid in a better prognosis,
diagnosis, clinical trial set up, and treatment plans for patients.
This paper clearly demonstrated that genetic markers are already being used in
collaboration with many other techniques to continue the medical advancements in neurological
and oncological research. The coming tables illustrate the common mutations found in all the
tumors mentioned throughout this paper; the percentage at which each mutation occurs; the uses
each mutation can be applied (i.e. diagnosis, prognosis) (S. Park et al 6-7).
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The tumors that were discussed have been underlined for easy detecting in tables 4 that
can be found under Appendix G. For common mutations consult table 5, under Appendix H
As for screening test, there were not any true screening test for brain tumors in patient
who had not already had an initial tumor removed, or expressed symptoms that correlated to
brain tumors. It’s a fair speculation that this has not been done yet because the idea may seem
invasive; or that the plethora of mutations to look through may offer more complexity than
solutions in a screening examination. Nevertheless, the option should be further explored, similar
to that of the clinical approaches mentioned in Chapter 3, that took permission and certifications
to propose the clinical trials.
The hope is that, there can be a computer system where one can input all the significant
mutations of the most commonly researched tumors, and screen spinal fluid to detect any
possible DNA alterations that may indicate the presence of tumors. This test could be optional,
for people to take at their leisure, or mandatory for everyone, and covered by insurance
companies, like mammograms to screen for breast cancer. The test that are mandated could be
regulated based on the environmental and occupational factors that are likely to increase
risk/susceptibility of brain tumors, and those who live or work in instances that correlate to the
instances mentioned in this paper would be required to take screening tests at set interval of
months or years depending on age, to assure population health.

Other ways to create proper screening techniques would be creating profiles that include patient
history and family history, this would be one step in the right direction towards better targeting
patient needs which give clarity to doctors as to how to better approach overall brain tumor
assessment. This proposal, will obviously take some time before it can be implemented, the
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necessities of this type of procedure for screening would need permission, specimens, data, and
consent from patients and nation originations such as WHO, NIH, CDC, and others. In addition
to these safety parameters, there would need to be a computer system with the ability to take a
surplus information and assess correlations and commonalities among specimens and patient
information, with the ability to disregard repetitive findings. This system should also have a selfchecking parameter encoded so that errors, such as incorrect matching of information, or
incorrect correlations to brain tumor susceptibility and mutations can be avoided in assessment.
Generally, this concept still needs work, but it is certainly applicable given the right foundations
of support. Therefore, the hypothesis of genetic markers capabilities is validated. They offer a
large magnitude of information in better treatment, diagnosis, and prognosis. The further the
field of oncology proceeds in the use of genetic markers as a way to tackle the big monster that
brain tumors are, the more likely we will be able to better treat and help alleviate the pain and
burden inflicted on patients by brain tumors.
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Appendices
Appendix A

Overall survival (OS)- A term to describe how long a patient will survive post diagnosis or post
treatment.
Progression-Free Survival (PFS)- A term to that assesses how long a patient will survive without
recurrence/regrowth of a tumor after resection.
Magnetic Resonance Imaging (MRI)- A medical imaging technique that uses radio waves and a
computer to generate pictures of areas inside the human body.
White matter (WM)- Sections of the brain tissue that is pale (white color appearance), consist of
nerve fibers, located between the gray matter which makes majority of the peripheral tissue of
the brain.
Computed Tomography scan (CT)- A medical technique that uses multiple x-ray images/pictures
attained from different angles at different “slice” thickness, combined with a computer to
generate images that offer anatomical views of organs and tissues in depth.
Polymerase chain reaction (PCR)- A technique used in molecular applications which can amplify
single copies or segments of DNA.
Response rate (RR)- The rate at which a patient responds to a particular treatment
Apoptosis – this is programmed cell death, where the cell itself enters the pathway that enables it
to destroy itself due to damage.
Necrosis- cell death that is random, and not programmed. Could be caused by cell damage
Atypia- This term describes cells that appear atypical or abnormal from the original
morphological appearance.
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Prognosis- The prediction or forecast of the likely course of a disease and patients’ mortality.
Diagnosis- The identification of a disease.
Polymerase Chain Reaction (PCR)- A laboratory technique/protocol that analyzes a short
sequence of DNA, through amplification of targeted DNA through the use of probes and
amplifiers.
Metastasis- The spread of a malignant growth in a secondary phase, either in surrounding tissue
or other organs.
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Appendix B

•

Pesticide applicators
o A suspected three-fold increased risk due to agricultural chemicals

•

Petrochemical refineries
o A proposed increased risk of gliomas for workers in petrochemical industry is
believed to be the result of exposures to a number of occupational factors. (
chemicals such as organic solvents, aromatic acids, plastic monomers or

•

Synthetic rubber manufacturing
o “exposure to synthetic rubber products is reported to increase the risk of
glioma.

•
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Exposures to plastics are reported to increase glioma risk”

Firefighters
o Marginally increased risk

•

Veterinarians
o Increased risk

•
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Electricity generation workers

o Glioma, but not meningioma risk was associated with the duration of job
involving exposure to electric and magnetic fields. The risk increased with the
duration of the exposure (p=0.05 for trend). The risk was greatest for
astrocytoma (OR=4.3; 95% CI: 1.2–15.6).
The reader should note that the work done by an electrical engineer exposes them to
electric and magnetic fields, and that in the article published by The African Health Sciences
Makerere Medical School , focused on exposure to children and correlation to incidence, while
The International Journal of Occupational and Environmental Medicine assessed the correlation
of increased risk and incidence in adults through occupational and environmental perspectives.
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Appendix C – Table 1
Formulating concept of how CNS tumor diagnoses are structured in the molecular era
Major restructuring of diffuse gliomas, with incorporation of genetically defined entities
Major restructuring of medulloblastomas, with incorporation of genetically defined entities
Major restructuring of other embryonal tumors, with incorporation of genetically defined entities
and removal of the term “primitive neuroectodermal tumor”
Incorporation of a genetically defined ependymoma variant
Novel approach distinguishing pediatric look-alikes, including designation of novel, genetically
defined entity
Addition of newly recognized entities, variants and patterns IDH-wildtype and IDH-mutant
glioblastoma (entities) Diffuse midline glioma, H3 K27M–mutant (entity) Embryonal tumour
with multilayered rosettes, C19MC-altered (entity) Ependymoma, RELA fusion–positive (entity)
Diffuse leptomeningeal glioneuronal tumor (entity) Anaplastic PXA (entity) Epithelioid
glioblastoma (variant) Glioblastoma with primitive neuronal component (pattern) Multinodular
and vacuolated pattern of ganglion cell tumor (pattern) Deletion of former entities, variants and
terms
Gliomatosis cerebri
Protoplasmic and fibrillary astrocytoma variants
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Cellular ependymoma variant
“Primitive neuroectodermal tumour” terminology
Addition of brain invasion as a criterion for atypical meningioma
Restructuring of solitary fibrous tumor and hemangiopericytoma (SFT/HPC) as one entity and
adapting a grading system to accommodate this change
Expansion and clarification of entities included in nerve sheath tumors, with addition of hybrid
nerve sheath tumors and separation of melanotic schwannoma from other schwannomas
Expansion of entities included in hematopoietic/lymphoid tumors of the CNS (lymphomas and
histiocytic tumors)
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Appendix D- Table 2
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Appendix E- Table 3Brain tumors common in children:
Medulloblastoma
•

Medulloblastoma has a peak incidence in childhood but also can occur into late
middle age.

•

Histologically childhood and adult medulloblastoma are identical, being highly
cellular, malignant invasive tumours corresponding to WHO malig- nancy grade IV.

•

Medulloblastomas occur in the posterior fossa. They consist of densely packed
tumour cells with round to oval or carrot shaped hyperchromatic nuclei with scanty
cytoplasm, high mitotic and apoptotic rates, and usually neuroblastic rosettes in some
areas.

•

The most common chromosomal abnormality in medullo- blastomas is isochromosome 17q, in which most of the short arm is lost from two chromosomes 17
and they are then fused head-to-head producing a chromosome with two centromers,
little 17p and two 17q arms. This is observed in 30–50% of cases by using
cytogenetic techniques .

Ependymoma
•

The most common location is in the fourth ventricle, followed by the spinal canal,
lateral ventricles, and the third ventricle.
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•

Children have the highest incidence of ependymomas, but they can occur into late
middle age.

•

There are a number of subtypes. The least biologically aggressive are malignancy
graded as grade 1, and consist of the subependymoma (intraventricular and often
symptomless) and myxopapillary ependymoma that most commonly occurs at the
cauda equina.

•

The tumour named ependymoma is malignancy graded as grade II and has a number
of histopathological variants. Ependymomas show in some area(s) evidence of an
ependymal cell phenotype—by the formation of ependymal rosettes and sometimes
canals

•

These findings have been confirmed by molecular genetic data that have identified
losses on 6q, 9p, 10, 11q, 13q, 17p and 19q.

Pilocytic astrocytomas
•

Patients with pilocytic astrocytomas that can be excised have a good prognosis.

•

Pilocytic astrocytomas are generally biologically non-aggressive and are remarkable
among astrocytic tumours in maintaining their grade I status over years and even
decades (in contrast to the diffuse astrocytic tumours in adults).

•

Pilocytic astrocytomas show a wide spectrum of morphologies, from the pilocytic,
bipolar cellular areas with Rosenthal fibers (fig 1) to less cellular protoplasmic
astrocytoma-like areas with eosinophilic granular bodies and clear cells.
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•

Pilocytic astrocytomas most commonly occur in the cerebellum of children. However,
they may occur anywhere from the optic nerve to the medulla oblongata.

Brain tumors common in adults
Meningiomas
•

Meningiomas are usually solitary lobulated tumours arising in the meninges and
attached to the dura. They are believed to develop from meningothelial (arachnoidal)
cells, despite the fact that the meningothelial form is far from the most common.

•

Symptomatic meningiomas represent 13–26% of primary intracranial tumours, are
most common in middle aged and elderly patients, and show a pronounced female
predominance.

•

meningiomas may progress from grade I tumours to tumours of higher malignancy
grade. This is associated with losses on chromosomal arms 1p, 6q, 9p, 10p and q,
14q, 18q, as well as gains and some amplifications on many other chromosomes

Oligodendrogliomas
•

Oligodendrogliomas occur mainly in the cerebral hemi- spheres of adults.

•

They are believed to derive from oligodendrocytes.

•

Increases in nuclear pleomorphism and hyperchromatism, as well as pronounced
hypercellularity, brisk mitotic activity, prominent microvascular proliferation, and/or
spontaneous necrosis, results in a picture that is histologically classified as anaplastic
oligodendroglioma (malignancy grade III).
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•

Oligodendrogliomas show relatively specific genetic abnormalities that differ from
the other gliomas. Loss of genetic information from 1p and 19p was demonstrated in
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a genomic wide analysis in 1994 and this was later linked to a good response to PCV
treatment, an association that is currently under intense scrutiny as it provides the first
molecular indicator of treatment response in brain tumours.
•

The losses on 1p and 19q are most common among the grade II oligodendrogliomas
(reports of up to 90%) and are present in over 50% of anaplastic oligodendrogliomas
(malignancy grade III).

Diffuse astrocytic tumors
•

The adult diffuse astrocytic tumours include the astrocytomas (malignancy grade II), the
anaplastic astrocytomas (malignancy grade III), and the glioblastomas (malignancy grade
IV).

•

The astrocytoma malignancy grade II tumours have a peak incidence between 25 and 50
years of age, while the glioblastomas have a peak incidence between 45 and 70 years.

•

All are more common in males and most are located in the cerebral hemispheres.

•

Anaplastic astrocytomas (malignancy grade III) show increased cellularity but the tumour
cells still show histological and immunocytochemical characteristics of astrocytes.

•

Cytogenetics, CGH, and molecular genetic techniques all show that the losses of alleles
on 6q, 13q, 17p and 22q, as seen in the astrocytoma malignancy grade II, occur at similar
or higher frequencies in the anaplastic astrocytomas.
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•

In addition to the genetic abnormalities resulting in the disruption of the p53 and Rb1
pathways, over 90% of glioblastomas lose alleles from 10q. The regions consistently lost
include the variously named PTEN/MMAC1/TEP1 tumour suppressor gene at 10q23–24.
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Appendix F

•

VSA revealed that patients with tumors intersecting the right anterior thalamic radiation
(ATR), right inferior fronto-occipital fasciculus (IFOF), bilateral corticospinal tracts
(CSTs), and corpus callosum (CC) had decreased OS com- pared to patients with tumors
intersecting WM tracts else- where

•

Interestingly, age turned out to be a factor with tumor location. A large cluster in the
posterior left parietal lobe was associated with younger patients, while a smaller subset of
clusters in the right frontal lobe was associated with older patients.

•

Tumors intersecting the right ATR, right IFOF, right and left CST, and CC were
associated with decreased OS.

•

Tumors intersecting the CST, body of the CC, right ATR, posterior IFOF, and IFL are
associated with decreased PFS, while tumors intersecting the right genu of the CC and
anterior IFOF are associated with increased PFS.

•

Subjects who had bevacizumab have a significantly improved survival prognosis if their
tumors intersect the ATR, IFOF, CST, or CC.
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Appendix G- Table 4

WHO

Genomic
Altered genes

grade

Astrocytoma

Glioblastoma

48

II, III

IV

alteration (%)

IDH mutation

65

P53 mutation

96

ATRX mutation

96

EGFR amplification

57

PDGFRA amplification

13

EGFRvIII mutation

20

PTEN homozygous deletion

25–35

WHO

Genomic
Altered genes

grade

alteration (%)

CDKN2A homozygous deletion

61

BRAF V600E mutation

1–2 (epithelioid
GBM)

Oligodendroglioma

49

II, III

TP53 mutation

25–35

IDH mutation

100

1p/19q codeletion

100

CIC/FUBP1 mutation

56/29

TERTp mutation

80–96

WHO

Genomic
Altered genes

grade

Subependymal giant cell

alteration (%)

I

TSC1 and TSC2 mutation

100

I

BRAF-KIAA1549 fusion

75 (cerebellar

astrocytoma

Pilocytic astrocytoma

tumor)

Pleomorphic

II, III

BRAF V600E mutation

13–15

BRAF V600E mutation

66

CDKN2A homozygous deletion

50

xanthoastrocytoma

Angiocentric glioma

I

MYB-QKI fusion

100

Ganglioglioma

I, III

BRAF V600E mutation

25

50

WHO

Genomic
Altered genes

grade

alteration (%)

TSC1 and TSC2 mutation

Unknown

BRAF V600E mutation

100

I

CTNNB1 mutation

100

IV

SMARCB1 deletion/mutation

> 95

IV

SMARCA4 mutation

<5

Cribriform tumor

SMACB1 deletion/mutation

100

Meningioma, fibrous type

NF2 inactivation mutation (no hot 45–5550

Craniopharyngioma, papillary I
type

Craniopharyngioma,
adamantinomatous type

AT/RT

spot)

51

WHO

Genomic
Altered genes

grade

alteration (%)

TRAF7/KLF4 mutation

100 (secretory
meningioma)

Langerhans cell histiocytosis I, III

52

AKT1 (p.Glu17Lys) mutation

2.5

SMO (p.Trp535Leu) mutation

5

TERTp mutation

10

BRAF V600E mutation

50–5754

Appendix H - Table 5

Target probe Control

1p deletion

Chr1p36

1q25

Cut off

1p < 0.8

Indication

ODG

Biomarker

Diagnostic,

and

prognostic,

Deleted

and predictive

nuclei >
50%

19q deletion

Chr19q13

19p13

19q < 0.8 ODG, HGG

Diagnostic,

and

prognostic,

Deleted

and predictive

nuclei >
50%

BRAF gain

Chr7q34

CEP7

Gold
signal > 3

PA

Diagnostic,
prognostic,
and predictive

53

Target probe Control

CDKN2A (9p21.3)

Chr9p21.3

CEP9

homozygous/hemizygous

Cut off

HoD ≥

Indication

HGG

10%

Biomarker

Diagnostic and
prognostic

deletion
HeD ≥
50%

EGFR amplification

Chr711.2

CEP7

Ratio ≥ 2.0 HGG

Diagnostic and
prognostic

PTEN HoD /HeD

Chr10q23.31 CEP10

HoD ≥

HGG

10%

Diagnostic and
prognostic

HeD ≥
50%

RELA-C11orf95 fusion

54

Chr11q13.1

CEP11

Break

S-

Diagnostic and

apart

ependymoma prognostic

Target probe Control

C19MC amplification

Chr19

CEP19

Cut off

Indication

Ratio ≥ 2.0 ODG, GBM

Biomarker

Diagnostic and
prognostic

SMARCB1

Chr22q11.23 CEP22

NF2 < 0.8 AT/RT

Diagnostic and
prognostic

55
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